The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...

Intercept said it will work with the FDA on next steps, and the drug remains on the market. PBC is a rare and chronic liver ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...

Aug. 21, 2024 — A research team has shown the benefits of camu-camu on non-alcoholic fatty liver disease. This exotic fruit reduces liver fat ... Liver Transplant Outperforms Other Therapies for ...

Experts warn that fatty liver disease (FLD) is becoming an epidemic in India, driven by genetics and lifestyle. With a ...

Mr McHugh said he was puzzled to receive a letter out of the blue as he had "no symptoms". Two weeks later, Mr McHugh had an ...

Bilirubin, the byproduct of hemoprotein breakdown, particularly hemoglobin, is a critical marker in diagnosing, prognosing, ...

Liver diseases, both acute and chronic, continue to pose significant clinical challenges due to high morbidity and mortality ...

The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Deaths caused by this disease more than tripled between 2017 to 2019 and it is now the fastest rising cause of cancer deaths ...

Non-alcoholic fatty liver disease (NAFLD) has emerged as a growing concern in liver cancer development. This condition, often ...